BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21820407)

  • 1. Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD.
    Razumovskaya E; Sun J; Rönnstrand L
    Biochem Biophys Res Commun; 2011 Aug; 412(2):307-12. PubMed ID: 21820407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance.
    Fleischmann M; Fischer M; Schnetzke U; Fortner C; Kirkpatrick J; Heidel FH; Hochhaus A; Scholl S
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway.
    Tatake RJ; O'Neill MM; Kennedy CA; Wayne AL; Jakes S; Wu D; Kugler SZ; Kashem MA; Kaplita P; Snow RJ
    Biochem Biophys Res Commun; 2008 Dec; 377(1):120-5. PubMed ID: 18834865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
    Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
    Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT; Levis M; Small D
    Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
    Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
    Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
    Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
    Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
    J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.
    Scheijen B; Ngo HT; Kang H; Griffin JD
    Oncogene; 2004 Apr; 23(19):3338-49. PubMed ID: 14981546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
    Nishioka C; Ikezoe T; Yang J; Takeshita A; Taniguchi A; Komatsu N; Togitani K; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Jun; 32(6):865-72. PubMed ID: 17983653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
    Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S
    Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.
    Kazi JU; Chougule RA; Li T; Su X; Moharram SA; Rupar K; Marhäll A; Gazi M; Sun J; Zhao H; Rönnstrand L
    Cell Mol Life Sci; 2017 Jul; 74(14):2679-2688. PubMed ID: 28271164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
    Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
    J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.